Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

CompletedOBSERVATIONAL

Enrollment

2,336

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

May 9, 2021

Study Completion Date

September 1, 2022

Conditions

Cancer

Interventions

DRUG

olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib

All patients treated at least with 1 PARPi (alone or in combination)

Trial Locations (1)

Alexandre Joachim, Caen

All Listed Sponsors

lead

University Hospital, Caen

OTHER

NCT04774406 - Arterial Hypertension Related to PARP Inhibitors (ArteRIB) | Biotech Hunter | Biotech Hunter